Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 2
2001 1
2003 2
2005 1
2006 5
2007 5
2008 6
2009 10
2010 17
2011 13
2012 15
2013 13
2014 14
2015 12
2016 11
2017 15
2018 16
2019 22
2020 22
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

185 results
Results by year
Filters applied: . Clear all
Page 1
Pralatrexate for lymphoma.
[No authors listed] [No authors listed] Aust Prescr. 2019 Apr;42(2):77. doi: 10.18773/austprescr.2019.020. Epub 2019 Feb 28. Aust Prescr. 2019. PMID: 31048945 Free PMC article. Review. No abstract available.
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. O'Connor OA, et al. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245435 Free PMC article. Clinical Trial.
RESULTS: Of 115 patients enrolled, 111 were treated with pralatrexate. The median number of prior systemic therapies was three (range, 1 to 12). ...These data formed the basis for the US Food and Drug Administration approval of pralatrexate, the first drug approved …
RESULTS: Of 115 patients enrolled, 111 were treated with pralatrexate. The median number of prior systemic therapies was three (range …
Pralatrexate.
[No authors listed] [No authors listed] 2016 May 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31643237 Free Books & Documents. Review.
Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T cell lymphomas. Pralatrexate has been associated with a modest rate of serum enzyme elevations during therapy, but has not been convincingly
Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T cell ly
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. Amengual JE, et al. Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15. Blood. 2018. PMID: 29141948 Free PMC article. Clinical Trial.
Patients were treated with pralatrexate (10 to 25 mg/m(2)) and romidepsin (12 to 14 mg/m(2)) on 1 of 3 schedules: every week 3 every 28 days, every week 2 every 21 days, and every other week every 28 days. ...The overall response rate was 57% (13/23) across all pati …
Patients were treated with pralatrexate (10 to 25 mg/m(2)) and romidepsin (12 to 14 mg/m(2)) on 1 of 3 schedules: every week 3 …
Methotrexate and Pralatrexate.
Wood GS, Wu J. Wood GS, et al. Dermatol Clin. 2015 Oct;33(4):747-55. doi: 10.1016/j.det.2015.05.009. Epub 2015 Aug 1. Dermatol Clin. 2015. PMID: 26433846 Free PMC article. Review.
This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorders. ...
This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphoma …
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong JY, Yoon DH, Yoon SE, Kim SJ, Lee HS, Eom HS, Lee HW, Shin DY, Koh Y, Yoon SS, Jo JC, Kim JS, Kim SJ, Cho SH, Lee WS, Won JH, Kim WS, Suh C. Hong JY, et al. Sci Rep. 2019 Dec 30;9(1):20302. doi: 10.1038/s41598-019-56891-0. Sci Rep. 2019. PMID: 31889144 Free PMC article.
Between December 2012 and December 2016, a total of 38 patients with relapsed or refractory PTCLs were treated with pralatrexate at 10 tertiary hospitals in Korea. Patients received an intravenous infusion of pralatrexate at a dose of 30 mg/m(2)/week for 6 we …
Between December 2012 and December 2016, a total of 38 patients with relapsed or refractory PTCLs were treated with pralatrexate at …
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X, Song Y, Huang H, Bai B, Zhang H, Ke X, Shi Y, Zhu J, Lu G, Liebscher S, Cai C. Hong X, et al. Target Oncol. 2019 Apr;14(2):149-158. doi: 10.1007/s11523-019-00630-y. Target Oncol. 2019. PMID: 30904980 Free PMC article. Clinical Trial.
OBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL. ...CONCLUS …
OBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate wer …
Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
O'Connor OA, Amengual J, Colbourn D, Deng C, Sawas A. O'Connor OA, et al. Leuk Lymphoma. 2017 Nov;58(11):2548-2557. doi: 10.1080/10428194.2017.1306642. Leuk Lymphoma. 2017. PMID: 28738754 Review.
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). ...In this review, we will bring the reader up to date on the many new aspec …
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatme …
Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates.
Malhotra U, Mukherjee S, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani N. Malhotra U, et al. Mol Cancer Ther. 2020 Jan;19(1):304-311. doi: 10.1158/1535-7163.MCT-19-0240. Epub 2019 Oct 1. Mol Cancer Ther. 2020. PMID: 31575653 Free article. Clinical Trial.
The purpose of our study was to evaluate the efficacy of a combination of pralatrexate plus oxaliplatin in advanced esophagogastric cancer (EGC), analyze the impact of polymorphisms in folate metabolism pathway genes on toxicity and efficacy of pralatrexate, and to …
The purpose of our study was to evaluate the efficacy of a combination of pralatrexate plus oxaliplatin in advanced esophagogastric c …
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR. Molina JR. IDrugs. 2008 Jul;11(7):508-21. IDrugs. 2008. PMID: 18600598 Review.
Pralatrexate, a 10-deazaaminopterin derivative, is being developed by Allos Therapeutics Inc for the potential treatment of malignancies. ...The administration of pralatrexate to patients with T-cell lymphomas and NSCLC resulted in significant tumor re
Pralatrexate, a 10-deazaaminopterin derivative, is being developed by Allos Therapeutics Inc for the potential treatmen
185 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page